Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.22 CAD | +2.22% | +6.27% | +192.73% |
May. 14 | Cardiol Therapeutics Says Phase II ARCHER Trial Presented at World Congress on Acute Heart Failure | MT |
Apr. 22 | HC Wainwright Starts Cardiol Therapeutics With Buy Rating, $9 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+192.73% | 161M | |
+33.37% | 50.85B | |
+1.55% | 42.82B | |
+49.28% | 42.03B | |
-4.22% | 29.55B | |
+11.57% | 26.11B | |
-21.00% | 19.13B | |
+7.36% | 13.05B | |
+28.30% | 12.16B | |
+23.80% | 12.08B |
- Stock Market
- Equities
- CRDL Stock
- News Cardiol Therapeutics Inc.
- Cardiol Therapeutics Enrolls Over 50% of Patients for Phase II ARCHER Trial in Acute Myocarditis